drugset
drugset / Trial / NCT04852419

A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS

NCT04852419 ↗

Phase 1 Completed 12 enrolled Zentera Therapeutics HK Limited
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this phase 1b study in Chinese patients with ER+/Her2- advanced breast cancer is to evaluate the safety and tolerability of ZN-c5 at dose of 50 mg and 150 mg QD well tolerance established in the previous oversea study in non-Chinese patients.

Timeline

Start
2021-05-31
Primary completion
2022-06-23
Completion
2022-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ZN-c5 Unknown 50 mg Oral
Subject ZN-c5 Unknown 150 mg Oral

Indications

breast cancer